Experience Matters
Providing expert advice in market access, health economics, pricing & reimbursement and regulatory affairs in Australia, New Zealand and the Asia Pacific region.
Welcome to Lucid Health Consulting: Your Gateway to Pharmaceutical and Medical Markets in Australia and the Asia-Pacific
With over 30 years of industry leadership, Lucid Health Consulting is the trusted partner for companies and associations in the pharmaceuticals, medical device, medical technology, and biotech sectors in Australia.
Our team of experts includes health economists, regulatory affairs specialists, reimbursement and HTA consultants, market and patient access advisors, and statisticians. We have a proven track record of enabling companies and organisations to optimise the entry of their pharmaceuticals, biotech products medical devices and technologies into the Australian market.
Whether you’re looking to overcome complex regulatory hurdles, answer critical business questions, streamline your market entry process or require product sponsorship in Australia, we are here to help.
Let us help you unlock new opportunities and drive success across Australia and the Asia-Pacific region.
How we can help your business?
Market Access and Pricing Strategy
Reimbursement Submissions (PBAC, MSAC, LSDP, PL)
Regulatory Affairs, Compliance and Advocacy
Economic Modelling and Evaluations
Statistical Analyses, Research, and Market Intelligence
Product Sponsorship and Commercialisation
Unlock the potential of the Asia-Pacific Market with Lucid Health Consulting
Let us help facilitate your pathway to successful approval and launch of your pharmaceuticals, biotech products, medical devices, and technologies across the Asia-Pacific Region through our strategic partnership with Vista Health , headquartered in Singapore, with offices in Japan and the UK.
Together, we leverage our combined expertise and expansive network across the region to offer tailored advice, strategic insights, and seamless implementation, paving the way for your successful market entry across the Asia-Pacific region.
What’s New
Read our articles, find out about our upcoming webinars and speaking engagements for the latest industry insights.
AusMedtech 2021 – Reimagine & Reconnect online conference, 17 – 21 May.
Only 1 month until AusMedtech’s 2021 Reimagine & Reconnect online conference, 17 – 21 May. AusMedtech is Australia’s premier medical technology conference for medtech executives, providing business partnering opportunities for decision makers and investors,...
ISPOR VOS Research RoundUp | January – February 2021
Our Director at Lucid Health Consulting, George Papadopoulos, edited the ISPOR, Research RoundUp in the January - February 2021 Edition of the Value & Outcomes Spotlight. The latest issue of ISPOR’s Values & Outcomes Spotlight looks at vaccine hesitancy and...
Virtual ISPOR 2021 Conference, 17 – 20 May.
The Virtual ISPOR 2021 Conference will be live for 4 days from 17 – 20 May, tailored to a global audience, Virtual ISPOR 2021 is a great opportunity to interact with your peers in the HEOR community. The leading global conference for health economics and outcomes...
What our clients are saying.
The Lucid Health Consulting team did a fantastic job with our funding application. The indication was complex, with multiple sub-populations and a varied treatment pathway. But they put together a clear and well-reasoned clinical evaluation, and translated this into a compelling economic assessment.
Their broad experience and expertise meant they could provide valuable strategic insights throughout the submission process, ultimately leading to a positive recommendation the first time of asking – no mean feat. I would highly recommend their services.
Market Access Manager, Takeda.
The Lucid team’s thoughtful consideration of the strategic direction of a submission, their expert economic modelling skills and their ability to draw out the narrative of the value proposition ensures that the overall cost-effectiveness outcome is compelling to technical evaluators and general payers alike.
Head of Patient Services & Government Affairs ANZ, Baxalta
Lucid Heath Consulting are excellent to work with. All of their work is both scientifically rigorous and clearly articulated. Our very complex case was presented to us in a compelling way.
The Directors at Lucid Health Consulting, have a great hands on approach and good direct dialogue with the relevant people in our organisation.
We enjoyed working with Lucid Health Consulting and would recommend them and use them ourselves for our future projects.
Executive Director Integrated Market Access, Janssen-Cilag
At Tryptamine Therapeutics Limited, we are a clinical-stage biotechnology company dedicated on bringing transformative medicines with established safety profiles for diseases lacking effective first-line treatments. Our lead program, TRP-8803, is an intravenous (IV) infusion of psilocin (the active metabolite of psilocybin) which is designed to overcome many of the limitations associated with orally administered psilocybin currently used by most competitors in the field.
To support the registration and reimbursement of TRP-8803 in Australia, we engaged Lucid Health Consulting. Their team has played a pivotal role in advancing both the product registration process and the development of a robust reimbursement strategy. This includes ongoing engagement with the Therapeutic Goods Administration (TGA) and other key stakeholders in the Australian regulatory landscape.
We have worked with Lucid Health Consulting for two years and consistently found them to be true experts in their field. Their deep industry knowledge, comprehensive understanding of Australia’s reimbursement environment, and responsiveness to client needs have been invaluable. We highly recommend Lucid Health Consulting to any organisation seeking expert guidance on market access strategies in the Australian healthcare landscape.
Lucid Health Consulting are proud members of
Lucid Health Consulting are providers of expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia. Enabling companies to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.